- $166.40m
- $141.54m
- $32.55m
- 47
- 20
- 94
- 54
Growth & Value
12m Forecast Rolling | Industry | Market | |
---|---|---|---|
PE Ratio (f) | n/a | ||
PEG Ratio (f) | n/a | ||
EPS Growth (f) | n/a | ||
Dividend Yield (f) | n/a |
Valuation (ttm) | Industry | Market | |
---|---|---|---|
Price to Book Value | 6.73 | ||
Price to Tang. Book | 6.73 | ||
Price to Free Cashflow | n/a | ||
Price to Sales | 5.11 | ||
EV to EBITDA | n/a |
Shareholder Activity
Type | Buy / Hold / Sell |
---|---|
Institutions | |
Directors | |
Community |
Guru Screens
Quality
Name | Industry | Market | |
---|---|---|---|
Return on Capital | -19.35% | ||
Return on Equity | -36.69% | ||
Operating Margin | -19.07% |
Financial Summary
Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
---|---|---|---|---|---|---|---|---|---|
Total Revenue | $m | 7.58 | 13.86 | 15.56 | 19.24 | 32.55 | 50.74 | 61.78 | 53.36% |
Operating Profit | m | ||||||||
Net Profit | m | ||||||||
EPS Reported | |||||||||
Diluted Normalised EPS | |||||||||
EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
PE Ratio | x | ||||||||
PEG | |||||||||
Profitability | |||||||||
Operating Margin | % | ||||||||
ROA | % | ||||||||
ROCE | % | ||||||||
ROE | % | ||||||||
Cashflow | |||||||||
Op. Cashflow ps | |||||||||
Capex ps | |||||||||
Free Cashflow ps | |||||||||
Dividends | |||||||||
Dividend ps | |||||||||
Dividend Growth | % | ||||||||
Dividend Yield | % | ||||||||
Dividend Cover | x | ||||||||
Balance Sheet | |||||||||
Cash etc | m | ||||||||
Working Capital | m | ||||||||
NFA | m | ||||||||
Net Debt | m | ||||||||
Book Value | m | ||||||||
Diluted Weighted Average Shares | m | ||||||||
Book Value ps |
Other Ratios
Leverage (ttm) | Total | - Intang | + Pension |
---|---|---|---|
Gross Gearing | |||
Net Gearing | |||
Cash / Assets |
Liquidity (ttm) | |
---|---|
Curr. Ratio | |
Quick Ratio | |
Interest Cov. |
Efficiency (ttm) | |
---|---|
Asset Turnover | |
Recs Turnover | |
Stock Turnover |
Recent History
Latest interim period vs. prior period | Industry | Market | |
---|---|---|---|
Sales Growth | |||
EPS Growth |
3yr Compound Annual Growth Rate | Industry | Market | |
---|---|---|---|
Sales CAGR | |||
EPS CAGR | |||
DPS CAGR |
Profile Summary
Myomo, Inc. is a wearable medical robotics company that offers improved arm and hand function for those suffering from neurological disorders and upper-limb paralysis. The Company develops and markets the MyoPro product line, which is a myoelectric-controlled upper limb brace, or orthosis. MyoPro is a powered upper-limb orthosis designed to support the arm and restore function to the weakened or paralyzed arms of certain patients suffering from CVA stroke, brachial plexus injury, traumatic brain or spinal cord injury or other neuromuscular disease or injury. MyoPro senses a patient’s own electromyography (EMG) signals through non-invasive sensors on the arm and can restore an individual’s ability to perform activities of daily living, including feeding themselves, carrying objects and doing household tasks. MyoPro’s control technology utilizes an advanced human-machine interface based on non-invasive, patented electromyography, or EMG, control technology.
Directors
- Paul Gudonis CHM (67)
- David Henry CFO (59)
- Clifford Conneighton CMO
- Harry Kovelman OTH (62)
- Micah Mitchell OTH (45)
- Thomas Kirk LED (75)
- Thomas Crowley IND (74)
- Amy Knapp IND (65)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- September 1st, 2004
- Public Since
- June 12th, 2017
- No. of Shareholders
- 121
- No. of Employees
- 184
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
NYSE MKT
- Shares in Issue
- 34,381,125

- Address
- 137 Portland Street, 4Th Floor, BOSTON, 02114
- Web
- https://myomo.com/
- Phone
- +1 6179969058
- Auditors
- Marcum LLP
Upcoming Events for MYO
Myomo Inc Annual Shareholders Meeting
Myomo Inc Annual Shareholders Meeting
Q2 2025 Myomo Inc Earnings Release
Similar to MYO
Acme United
NYSE MKT
Alpha Pro Tech
NYSE MKT
Catheter Precision
NYSE MKT
Electromed
NYSE MKT
Infusystem Holdings
NYSE MKT
FAQ
As of Today at 22:10 UTC, shares in MYOMO are trading at $4.84. This share price information is delayed by 15 minutes.
Shares in MYOMO last closed at $4.84 and the price had moved by +41.52% over the past 365 days. In terms of relative price strength the MYOMO share price has outperformed the S&P500 Index by +30.63% over the past year.
The overall consensus recommendation for MYOMO is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreMYOMO does not currently pay a dividend.
MYOMO does not currently pay a dividend.
MYOMO does not currently pay a dividend.
To buy shares in MYOMO you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $4.84, shares in MYOMO had a market capitalisation of $166.40m.
Here are the trading details for MYOMO:
- Country of listing: United States
- Exchange: ASQ
- Ticker Symbol: MYO
Based on an overall assessment of its quality, value and momentum MYOMO is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in MYOMO is $9.25. That is 91.12% above the last closing price of $4.84.
Analysts covering MYOMO currently have a consensus Earnings Per Share (EPS) forecast of -$0.12 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like MYOMO. Over the past six months, its share price has outperformed the S&P500 Index by +35.67%.
As of the last closing price of $4.84, shares in MYOMO were trading -1.2% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The MYOMO PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $4.84.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
MYOMO's management team is headed by:
- Paul Gudonis - CHM
- David Henry - CFO
- Clifford Conneighton - CMO
- Harry Kovelman - OTH
- Micah Mitchell - OTH
- Thomas Kirk - LED
- Thomas Crowley - IND
- Amy Knapp - IND